Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma

Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA

(2022) Mika Casey et al.   Blood Advances

Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2021) Stephen M Ansell et al.   CLINICAL CANCER RESEARCH

Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis

(2021) Capucine L. Grandjean et al.   Science Advances

ATP and cancer immunosurveillance

(2021) Oliver Kepp et al.   EMBO JOURNAL

Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis

(2021) Roarke A. Kamber et al.   NATURE

The P2X7 Receptor in Tumor Immunity

(2021) Fabio Grassi et al.   Frontiers in Cell and Developmental Biology

The microenvironment of DLBCL is characterized by non-canonical macrophages recruited by tumor-derived CCL5

(2021) Benoît Manfroi et al.   Blood Advances

Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission

(2021) Mazyar Shadman et al.   BLOOD

A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of DLBCL

(2021) Kohta Miyawaki et al.   Blood Advances

On the mechanism of anti-CD39 immune checkpoint therapy

(2020) David Allard et al.   Journal for ImmunoTherapy of Cancer

Combination of CD47 and SIRPα constituting the "don't eat me signal" is a prognostic factor in diffuse large B‐cell lymphoma

(2020) Ryo Kazama et al.   CANCER SCIENCE

Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function

(2020) Yasuhiro Nagate et al.   LEUKEMIA

Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody

(2020) Kyohei Nakamura et al.   LEUKEMIA

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

(2020) Rui Yang et al.   Journal for ImmunoTherapy of Cancer

Cancer immunoediting and immune dysregulation in multiple myeloma

(2020) Kyohei Nakamura et al.   BLOOD

The adenosine pathway in immuno-oncology

(2020) Bertrand Allard et al.   Nature Reviews Clinical Oncology

Intercellular Calcium Signaling Induced by ATP Potentiates Macrophage Phagocytosis

(2019) Sara Zumerle et al.   Cell Reports

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

(2019) Ivan Perrot et al.   Cell Reports

Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count

(2019) Yan-Li Li et al.   BMC CANCER

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

(2019) Kyohei Nakamura et al.   Cellular & Molecular Immunology

EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2

(2019) Alexandre S. Cristino et al.   BLOOD

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endotoxin-induced autocrine ATP signaling inhibits neutrophil chemotaxis through enhancing myosin light chain phosphorylation

(2017) Xu Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

(2015) Colm Keane et al.   Lancet Haematology

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

(2014) D. W. Scott et al.   BLOOD

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial

(2014) S. Riihijarvi et al.   HAEMATOLOGICA

TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses

(2013) H. B. Cohen et al.   BLOOD

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV

(2008) V. Minard-Colin et al.   BLOOD